NCT03619044: The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-alpha Status in Patients With Metastatic Breast Cancer HER2 + and ER-alpha Neg Treated With Trastuzumab + Pertuzumab + Taxane (REVER)

NCT03619044
Breast Cancer Type: HER2+
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must be eligible according to the investigator for a treatment with trastuzumab (Herceptin) + pertuzumab (Perjeta) + taxane (Taxol) in the metastatic first line setting
Exclusions: Patients NOT affiliated to a Social Health Insurance in France; Patients with any previous treatment for metastatic disease
https://ClinicalTrials.gov/show/NCT03619044

Comments are closed.

Up ↑